Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,253
Total Claims
$5.6M
Drug Cost
867
Beneficiaries
$6,457
Cost/Patient
Risk Score Breakdown 16/100
Score components are additive. Read full methodology
Peer Comparison vs. 109,535 Physician Assistant providers
+798%
Cost per patient vs peers
$6,457 vs $719 avg
+735%
Brand preference vs peers
55.5% vs 6.7% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
🔎 Data Overview
Cost per patient is 798% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 6,197 claims · $5.4M
Generic: 4,963 claims · $65K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Aspart | 600 | $650K |
| Empagliflozin | 719 | $633K |
| Semaglutide | 345 | $475K |
| Insulin Glargine,hum.Rec.Anlog | 590 | $442K |
| Insulin Regular, Human | 239 | $398K |
| Pegvisomant | 12 | $298K |
| Dulaglutide | 167 | $265K |
| Insulin Lispro | 246 | $251K |
| Insulin Aspart | 165 | $192K |
| Insulin Detemir | 239 | $175K |
| Insulin Glargine,hum.Rec.Anlog | 164 | $167K |
| Insulin Degludec | 209 | $131K |
| Insulin Lispro | 103 | $126K |
| Sitagliptin Phosphate | 77 | $81K |
| Insulin Glargine,hum.Rec.Anlog | 165 | $78K |
Prescribing Profile
Patient Profile
71
Avg Age
58%
Female
1.92
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data